A hallmark of bone marrow changes with aging is the increase in adipocyte composition, but how this impacts development of multiple myeloma (MM) is unknown. Here, we report the role of the adipokine leptin as master regulator of anti-myeloma tumor immunity by modulating the invariant natural killer T (iNKT) cell function. A marked increase in serum leptin levels and leptin receptor (LR) expression on iNKT cells in MM patients and the 5T33 murine MM model was observed. MM cells and leptin synergistically counteracted anti-tumor functionality of both murine and human iNKT cells. In vivo blockade of LR signaling combined with iNKT stimulation resulted in superior anti-tumor protection. This was linked to persistent IFN-γ secretion upon repeated iNKT cell stimulation and a restoration of the dynamic antigen-induced motility arrest as observed by intravital microscopy, thereby showing alleviation of iNKT cell anergy. Overall our data reveal the LR axis as novel therapeutic target for checkpoint inhibition to treat MM.Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.146.

Original languageEnglish
Pages (from-to)2678-2685
Number of pages8
Issue number12
Early online date2017
Publication statusPublished - Dec 2017

    Research areas

  • Animals, Antibodies, Monoclonal, Antineoplastic Agents/pharmacology, Cell Line, Tumor, Cell Proliferation/drug effects, Cytokines/biosynthesis, Disease Models, Animal, Galactosylceramides/pharmacology, Humans, Leptin/metabolism, Lymphocyte Activation/drug effects, Mice, Mice, Knockout, Molecular Targeted Therapy, Multiple Myeloma/drug therapy, Natural Killer T-Cells/drug effects, Receptors, Leptin/antagonists & inhibitors, Xenograft Model Antitumor Assays

ID: 34911108